88 89 These approaches identified several genes within the MAPK and PI3K pathways as cooperating mutations for KrasG12D-driven PDAC. Similarly, recent assessment of kinases with the highest levels of absolute and differential expression in a panel of pancreatic cancer cell lines demonstrated significantly reduced cell number after knockdown of EGFR, Akt2, PLK2 or MET.90 This review will focus on PI3K pathway targeting in PDAC (see also table 2, PI3K pathway inhibitors under clinical investigation in PDAC). This evidence concerns the gene PIK3CA and pancreatic neoplasm.